<?xml version="1.0" encoding="UTF-8" standalone="no"?><information><Cell><NavigationPath><Stub><SubHeader0>Weight loss</SubHeader0><StubValue>â€ƒ5% or more</StubValue></Stub><HeaderValue>CPT-P</HeaderValue></NavigationPath><value>27</value><CellType>Numeric</CellType></Cell><Table><tableName>Patient characteristics at baseline</tableName><TableType>Subheader</TableType><tableOrder>Table 1</tableOrder><tableFooter>aPatients who were used to evaluate survival.CPT=irinotecan; P=cisplatin; VDS=vindesine; PS=performance status.</tableFooter></Table><Document><DocumentTitle>Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer</DocumentTitle><PMC>2747545</PMC></Document></information>